Most patients with<unk>  require immediate treatment.<unk>  is difficult to treat, and it does not respond to most available chemotherapeutic drugs. Many different treatments have been attempted, with limited success in certain patients: purine analogues (pentostatin, fludarabine, cladribine), chlorambucil, and various forms of combination chemotherapy regimens, including cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), etoposide, bleomycin (VAPEC-B). Alemtuzumab (Campath), an anti-CD52 monoclonal antibody that attacks white blood<unk> s, has been used in treatment with greater success than previous options. In one study of previously treated people with<unk> , people who had a complete response to alemtuzumab survived a median of 16 months after treatment. Some patients who successfully respond to treatment also undergo stem<unk>  transplantation to consolidate the response.
T-cell prolymphocytic leukemia
Aggressive NK-cell leukemia
B-cell prolymphocytic leukemia
T-lymphoblastic leukemia/lymphoma
T-cell acute lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia
Acute myeloblastic leukemia with maturation
Prolymphocytic leukemia